Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
Status:
Terminated
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if the antiviral combination of
telaprevir, pegylated Interferon Alfa 2a (PegIFN alfa-2a) and ribavirin (RBV) can prevent the
virus from coming back after the liver transplant.
Telaprevir, PegIFN alfa-2a, and RBV are different antiviral drugs that work in combination at
different stages of the HCV infection to stop the virus.